Quick Answer
Aquestive Therapeutics, Inc. reported Operating Income of -$71.05 million for fiscal year 2025.
Aquestive Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$71.05M | -130.9% |
| 2024 | -$30.77M | -103.8% |
| 2023 | -$15.10M | +64.1% |
| 2022 | -$42.07M | -21.3% |
| 2021 | -$34.68M | +19.1% |
| 2020 | -$42.89M | +18.6% |
| 2019 | -$52.67M | -7.6% |
| 2018 | -$48.93M | -43204.4% |
| 2017 | -$113.0K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$11.48M | -38.5% | -1.0% |
| June 30, 2025 | -$11.37M | -20769.1% | +41.3% |
| March 31, 2025 | -$19.36M | -116.2% | -133.6% |
| September 30, 2024 | -$8.29M | -248.8% | -15172.7% |
| June 30, 2024 | $55.0K | +101.3% | +100.6% |
| March 31, 2024 | -$8.96M | -94.5% | -276.8% |
| September 30, 2023 | -$2.38M | +73.2% | +43.5% |
| June 30, 2023 | -$4.21M | +67.0% | +8.6% |
- Aquestive Therapeutics, Inc. showed a decrease of -130.9% in Operating Income compared to the prior fiscal year.
- Over the 2017–2025 period, Aquestive Therapeutics, Inc.’s operating income has declined by 62777.0% (from -$113.0 thousand to -$71.05 million).
- The most recent figure is from Aquestive Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: